Cicchitto, G.; Cardillo, L.; de Martinis, C.; Sabatini, P.; Marchitiello, R.; Abate, G.; Rovetti, A.; Cavallera, A.; Apuzzo, C.; Ferrigno, F.;
et al. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant. Viruses 2022, 14, 650.
https://doi.org/10.3390/v14030650
AMA Style
Cicchitto G, Cardillo L, de Martinis C, Sabatini P, Marchitiello R, Abate G, Rovetti A, Cavallera A, Apuzzo C, Ferrigno F,
et al. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant. Viruses. 2022; 14(3):650.
https://doi.org/10.3390/v14030650
Chicago/Turabian Style
Cicchitto, Gaetano, Lorena Cardillo, Claudio de Martinis, Paola Sabatini, Rosita Marchitiello, Giovanna Abate, Adele Rovetti, Antonietta Cavallera, Camillo Apuzzo, Francesco Ferrigno,
and et al. 2022. "Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant" Viruses 14, no. 3: 650.
https://doi.org/10.3390/v14030650
APA Style
Cicchitto, G., Cardillo, L., de Martinis, C., Sabatini, P., Marchitiello, R., Abate, G., Rovetti, A., Cavallera, A., Apuzzo, C., Ferrigno, F., & Fusco, G.
(2022). Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant. Viruses, 14(3), 650.
https://doi.org/10.3390/v14030650
